ArticlePediatric nephrology (Berlin, Germany)2007
Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome?
Article in Pediatric nephrology (Berlin, Germany), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Systematic Review and Meta-Analysis of Rituximab for Steroid-Dependent or Frequently Relapsing Nephrotic Syndrome in Children.Frontiers in pediatrics · 2021Pooled it
- Rituximab efficiency in children with steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2010Trial
- Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children.Pediatric nephrology (Berlin, Germany) · 2009Trial
- Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.Pediatric nephrology (Berlin, Germany) · 2008Trial
- Emerging role of Rituximab in adult minimal change disease: a narrative review of clinical evidence, biomarkers and future perspectives.BMC nephrology · 2025Review
- The role of B lymphocyte subsets in nephrotic syndrome: functions, mechanisms, clinical significance and future perspectives.Frontiers in immunology · 2025Review
- Rituximab Therapy for Adults with Nephrotic Syndromes: Standard Schedules or B Cell-Targeted Therapy?Journal of clinical medicine · 2021Review
- CD80 Insights as Therapeutic Target in the Current and Future Treatment Options of Frequent-Relapse Minimal Change Disease.BioMed research international · 2021Review
- Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials.Pediatric nephrology (Berlin, Germany) · 2018Review
- Cost-Effectiveness of Administering Rituximab for Steroid-Dependent Nephrotic Syndrome and Frequently Relapsing Nephrotic Syndrome: A Preliminary Study in Japan.Scientific reports · 2017Article
- History of Nephrotic Syndrome and Evolution of its Treatment.Frontiers in pediatrics · 2016Review
- American Society of Nephrology quiz and questionnaire 2013: glomerulonephritis.Clinical journal of the American Society of Nephrology : CJASN · 2014Article
- Efficacy of rituximab therapy in children with refractory nephrotic syndrome: a prospective observational study in Shanghai.World journal of pediatrics : WJP · 2014Observational
- Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2013Article
- Childhood nephrotic syndrome--current and future therapies.Nature reviews. Nephrology · 2012Review
- Induction of remission following a single dose of rituximab alone in a patient with minimal change nephrotic syndrome.Clinical and experimental nephrology · 2011Article
- Rituximab and minimal change nephrotic syndrome: a therapeutic option.Clinical and experimental nephrology · 2011Review
- Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine.Pediatric nephrology (Berlin, Germany) · 2010Article
- Rituximab in refractory nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2010Article
- Nephrotic syndrome and rituximab: facts and perspectives.Pediatric nephrology (Berlin, Germany) · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We each have nephrotic patients who become steroid dependent and in whom multiple immunosuppressive agents are employed. There is a need to balance possible therapeutic benefits with drug toxicity. This case report describes such a patient, who has suffered from nephrotic syndrome for over 11 years and had become resistant to the usual therapies. He was therefore given a single dose of the anti-CD20 drug rituximab, to which he showed a prompt response, leaving him free of proteinuria for the past 10 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.